Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spherical nucleic acids for psoriasis gene expression
NL-OMON43337Active, not recruiting
- Sponsor
- Derphartox
- Start
- Dec 2016
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of XCUR17 in psoriasis, sponsored by Derphartox. Primary endpoint: TNF gene downregulation. Started Dec 2016; status: active, not recruiting.
02
Drugs
XCUR17
03
Conditions
psoriasis
Beyond the preview
Go deeper on NL-OMON43337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43337.